OGT launches new CytoSure Constitutional v3 +LOH array for genetic analysis of developmental disorders

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of its new CytoSure Constitutional v3 +LOH array for comprehensive genetic analysis of developmental delay disorders. Alongside the latest content for exon-level copy number variation (CNV) coverage, research-validated single nucleotide polymorphism (SNP) probes facilitate detection of loss of heterozygosity (LOH), enabling insightful and cost-effective analysis on a single array. The unique CNV content, already available on OGT’s CytoSure Constitutional v3 array, has received significant acclaim, with several major laboratories recently switching to this platform.

Utilising the latest discoveries from ClinGen and the Deciphering Developmental Disorders  (DDD) study, OGT has incorporated every known region of the genome linked to developmental disorders to deliver the most up-to-date array platform for CNV detection currently available. The CytoSure Constitutional v3 array content covers 502 targeted genes, with high probe density across the most biologically relevant regions enabling the detection of single-exon aberrations. Now with the addition of SNP probes on the new CytoSure Constitutional v3 +LOH array, a broader range of copy-neutral genetic factors can be investigated on a single array, including LOH and uniparental disomy (UPD). Moreover, the SNP probe coverage also functions as an additional validation of CNVs, reducing the need to perform follow-up investigations.

Powerful data analysis and interpretation of these advanced arrays is also streamlined with OGT’s CytoSure Interpret Software, which is provided with each array alongside full on-site training. Innovative features enable automated data analysis, minimising user intervention and maximising both consistency and speed of interpretation.

The new CytoSure Constitutional v3 +LOH array builds on the existing success of the Constitutional v3 array, which has seen significant uptake in major clinical research laboratories across Europe and North America. Adding to previous National Health Service (NHS) tender success, OGT’s platform was recently selected by the Cardiff and Vale Health Board (Wales, UK). This stringent selection process compared a variety of arrays, with OGT being chosen due to the quality of the content, which is set to enhance the service of regional NHS laboratories around the country.

West Midlands Regional Genetic Laboratory (WMRGL, Birmingham, UK) has also recently converted to OGT from an alternative supplier. Consultant Clinical Scientist at WMRGL, Dom McMullan explained:

Our decision to switch to OGT over alternative platforms was based largely on the quality of the evidence base behind the array design, allowing for a very comprehensive analysis of exons, genes and regions key in postnatal and prenatal applications. In addition the speed, flexibility and versatility of OGT’s software was very important in our decision making. Following a rigorous validation, we found this platform out-performed all others. The support provided by OGT during and after the transition has also been first-class

Product Manager at OGT, David Cook, commented:

The expansion of our rapidly growing array portfolio to offer powerful exon-level CNV content coupled with SNP probes delivers an uncompromising best of both worlds for clinical researchers. We are delighted to witness the rapid adoption of our technology by a number of additional, prestigious laboratories this year — which really attests to the quality of our arrays and also our dedicated customer support.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxford Gene Technology. (2019, June 24). OGT launches new CytoSure Constitutional v3 +LOH array for genetic analysis of developmental disorders. News-Medical. Retrieved on July 16, 2024 from https://www.news-medical.net/news/20160321/OGT-launches-new-CytoSure-Constitutional-v3-2bLOH-array-for-genetic-analysis-of-developmental-disorders.aspx.

  • MLA

    Oxford Gene Technology. "OGT launches new CytoSure Constitutional v3 +LOH array for genetic analysis of developmental disorders". News-Medical. 16 July 2024. <https://www.news-medical.net/news/20160321/OGT-launches-new-CytoSure-Constitutional-v3-2bLOH-array-for-genetic-analysis-of-developmental-disorders.aspx>.

  • Chicago

    Oxford Gene Technology. "OGT launches new CytoSure Constitutional v3 +LOH array for genetic analysis of developmental disorders". News-Medical. https://www.news-medical.net/news/20160321/OGT-launches-new-CytoSure-Constitutional-v3-2bLOH-array-for-genetic-analysis-of-developmental-disorders.aspx. (accessed July 16, 2024).

  • Harvard

    Oxford Gene Technology. 2019. OGT launches new CytoSure Constitutional v3 +LOH array for genetic analysis of developmental disorders. News-Medical, viewed 16 July 2024, https://www.news-medical.net/news/20160321/OGT-launches-new-CytoSure-Constitutional-v3-2bLOH-array-for-genetic-analysis-of-developmental-disorders.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Baylor Miraca Genetics Laboratories licenses SNP probe technology from OGT